Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction ...
Company to host investor conference call and webcast on January 4, 2023, at 8:00 a.m. ET to further discuss results BRISBANE, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: ...
Treatment with atacicept led to a statistically significant 42% reduction in UPCR compared with placebo at week 36. Atacicept, an investigational BAFF (B-cell activating factor)/APRIL (a proliferation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback